Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  ERYTECH Pharma    ERYP   FR0011471135

ERYTECH PHARMA (ERYP)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
01/14/2019 01/15/2019 01/16/2019 01/17/2019 01/18/2019 Date
6.885(c) 6.845(c) 6.7(c) 6.805(c) 6.98(c) Last
31 093 19 764 16 091 23 533 73 311 Volume
-2.96% -0.58% -2.12% +1.57% +2.57% Change
More quotes
Financials (EUR)
Sales 2018 7,03 M
EBIT 2018 -44,9 M
Net income 2018 -44,9 M
Finance 2018 134 M
Yield 2018 -
Sales 2019 7,57 M
EBIT 2019 -53,5 M
Net income 2019 -56,1 M
Finance 2019 75,6 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 -1,25x
EV / Sales2019 6,55x
Capitalization 125 M
More Financials
Company
ERYTECH Pharma is a French biopharmaceutical company providing new prospects for cancer patients. By encapsulating the asparaginase enzyme in red blood cells, has developed eryaspase/GRASPA®, an innovative treatment that destroys cancerous cells through starvation while significantly reducing side... 
More about the company
Surperformance© ratings of ERYTECH Pharma
Trading Rating : Investor Rating :
More Ratings
Latest news on ERYTECH PHARMA
01/18ERYTECH PHARMA : Presents TRYbeCA-1 Trial-in-Progress Poster at the 2019 ASCO GI..
AQ
2018ERYTECH PHARMA : Partners with New York Blood Center for Red Blood Cell Supply a..
GL
2018ERYTECH PHARMA : Reports Third Quarter 2018 Financial Results and Provides Busin..
GL
2018ERYTECH PHARMA : Expands Use of Medidata Cloud to Centrally Manage All Data for ..
AQ
2018ERYTECH PHARMA : to Host KOL Breakfast Symposium with Audio Webcast on November ..
GL
2018ERYTECH PHARMA : Announces Enrollment of First Patients in Phase 3 Clinical Tria..
GL
2018ERYTECH PHARMA : Announces Enrollment of First Patients in Phase 3 Clinical Tria..
AQ
2018ERYTECH PHARMA : Announces Enrollment of First Patients in Phase 3 Clinical Tria..
GL
2018ERYTECH PHARMA : to Attend Upcoming Investor Conferences
GL
2018ERYTECH PHARMA : to Attend Upcoming Investor Conferences
AQ
More news
Analyst Recommendations on ERYTECH PHARMA
More recommendations
Sector news : Bio Therapeutic Drugs
01/18Samsung Bioepis biosimilar to Roche's Herceptin wins FDA nod
RE
01/08NEKTAR THERAPEUTICS : Shares Up Tuesday as Gilead Collaboration Announced -- Mar..
DJ
01/08GlaxoSmithKline to look for early-stage assets - CEO
RE
01/08Lilly's Deal Boosts Its Cancer Arsenal -- WSJ
DJ
01/07Eli Lilly to Buy Loxo Oncology in $8 Billion Deal -- 5th Update
DJ
More sector news : Bio Therapeutic Drugs
Chart ERYTECH PHARMA
Duration : Period :
ERYTECH Pharma Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ERYTECH PHARMA
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 25,0 €
Spread / Average Target 259%
EPS Revisions
Managers
NameTitle
Gil Beyen Chairman, CEO & Head-Investor Relations
Eric Soyer Chief Operating & Financial Officer
Iman El-Hariry Chief Medical Officer
Alexander Scheer Chief Scientific Officer
Philippe Archinard Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ERYTECH PHARMA11.68%142
GILEAD SCIENCES10.60%89 493
VERTEX PHARMACEUTICALS14.97%49 757
REGENERON PHARMACEUTICALS11.75%44 532
GENMAB-4.59%9 536
NEUROCRINE BIOSCIENCES, INC.28.18%8 300